| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 57.9 | 22.5 |
| Gross profit | 44.3 | 7.9 |
| Profit before tax | 22.4 | -2.0 |
| Net income | 35.2 | -1.9 |
| EPS (diluted, $ a share) | $1.06 | $-0.07 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +157.9% |
|---|---|
| Gross margin | 76.5% |
| Operating margin | 39.7% |
10-Q filed with the SEC, NASDAQ: ETON. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Eton Pharmaceuticals, Inc.: key numbers
- Share price
- $63.88Close, Nov 16
- Market cap
- $1.84B
- Shares outstanding
- 28.84MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Eton Pharmaceuticals, Inc.
All →Eton Pharmaceuticals Chief Commercial Officer Ipek Erdogan-Trinkaus Sells $236K of Stock
Ipek Erdogan-Trinkaus, Chief Commercial Officer, sold 3,500 shares of Eton Pharmaceuticals, Inc. at $67.18 to $67.88 a share (average $67.41) in 2 transactions, worth $236K in total on Nov 10, 2026. Shares held after the trade: 4,081 (-22.1%).
- Value
- $236K
- Shares
- 3,500
- Average price
- $67.41
- Role
- Chief Commercial Officer
- Holding change
- -22.1%
- Trade date
- Nov 10, 2026
Eton Pharmaceuticals Insider Charles J. Casamento Sells $5.35M of Stock
Charles J. Casamento sold 80,555 shares of Eton Pharmaceuticals, Inc. at $64.33 to $67.87 a share (average $66.35) in 5 transactions, worth $5.35M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $5.35M
- Shares
- 80,555
- Average price
- $66.35
- Holding change
- -100.0%
- Trade date
- Nov 10, 2026
Eton Pharmaceuticals Earnings Call: Key Takeaways
Eton Pharmaceuticals delivered a massive Q3 2026 beat, driven by Hemangiol's full-quarter contribution and record patient counts across all branded products, significantly accelerating their long-term revenue and margin targets.
- Call
- Nov 5, 2026, 4:30 PM ET
Eton Pharmaceuticals Financial Results
Eton Pharmaceuticals reported record Q3 2026 revenue of $57.9 million, representing 158% year-over-year growth and surpassing its $200 million annualized revenue run rate goal ahead of schedule. The company achieved a 49% Adjusted EBITDA margin and raised its full-year 2026 revenue guidance to over $175 million.
- Term
- Q3 2026
“Eton delivered another record quarter, with revenue of $57.9 million, up 158% year over year, and surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule. The team also demonstrated exceptional operational execution, significantly expanding margins, and delivering an adjusted EBITDA margin of 49%.”
Sean Brynjelsen, CEO of Eton Pharmaceuticals
“We have also made transformational improvements to our pipeline in recent months with ASN-001 for infantile hemangiomas, and ET-900, our new program evaluating mecasermin in infantile and epileptic spasms.”
Sean Brynjelsen, CEO of Eton Pharmaceuticals
Eton Pharmaceuticals Clinical Trial Data
Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.
“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”
Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
- Counterparty
- Baylor College of Medicine